Description: AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Home Page: www.astrazeneca.in
Manyata Embassy Business Park
Bengaluru,
560045
India
Phone:
91 80 6774 8000
Officers
| Name | Title |
|---|---|
| Dr. Sanjeev Kumar Panchal | MD, Country President & Director |
| Ms. Bhavana Agrawal | Whole-Time Director & CFO |
| Mr. Pratap Rudra Bhuvanagiri | Legal Counsel |
| Ms. Manasa R. | Company Secretary & Compliance Officer |
| Ms. Smita Saha | Vice President of Human Resources |
| Mr. Ayush Kumar Agarwal | Interim Business Unit Head of Oncology & Director of Commercial Excellence |
| Mr. Praveen Akkinepally | Head of Oncology Business Unit |
| Mr. Vinay Sharma | Business Unit Head - Rare Disease unit |
| Mr. Pankaj S Jain | Legal Head |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 204.0528 |
| Price-to-Book MRQ: | 24.4572 |
| Price-to-Sales TTM: | 11.9137 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 940 |